This week we talk about the new Invokana approval; The ranitidine recalls that led CVS to suspend all sales; The 11 serious cybersecurity vulnerabilities identified by the FDA that could affect medical devices and hospital networks; Entresto’s expanded indication; and the investigative COPD treatment that was rejected.